

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-25. (Cancelled).

Claim 26 (Currently amended). A method for treating cancer comprising administering to an individual therapeutically effective amount[[s]] of:

(a) a first therapeutic agent comprising an antibody which binds to a polypeptide selected from the group consisting of:

- (i) amino acids 1 to 468 of SEQ ID NO:2;
- (ii) amino acids 24 to 468 of SEQ ID NO:2;
- (iii) amino acids 24 to 238 of SEQ ID NO:2;
- (iv) the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853;
- (v) the amino acid sequence of the mature polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853; and
- (vi) the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853;

and

(b) a second therapeutic agent selected from the group consisting of:

- (i) TRAIL;
- (ii) a tumor necrosis factor;
- (iii) a tumor necrosis factor blocking agent;
- (iv) an immunosuppressive agent;
- (v) an antibiotic;
- (vi) an anti-inflammatory agent;
- (vii) a chemotherapeutic agent; and
- (viii) a cytokine.

Claim 27 (Original). The method of claim 26, wherein said first therapeutic agent comprises an antibody which binds to a polypeptide consisting of amino acids 24 to 238 of SEQ ID NO:2.

Claim 28 (Original). The method of claim 26, wherein said first therapeutic agent comprises an antibody which binds to a polypeptide consisting of the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853.

Claim 29 (Original). The method of claim 26, wherein said antibody is an agonist of a polypeptide comprising amino acids 24 to 238 of SEQ ID NO:2.

Claim 30 (Original). The method of claim 26, wherein said antibody is an agonist of a polypeptide comprising the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853.

Claims 31-32 (Cancelled).

Claim 33 (Original). The method of claim 26, wherein said antibody is an agonistic antibody.

Claim 34 (Original). The method of claim 26, wherein said antibody is a monoclonal antibody.

Claim 35 (Original). The method of claim 26, wherein said antibody is a polyclonal antibody.

Claim 36 (Original). The method of claim 26, wherein said antibody is a chimeric antibody.

Claim 37 (Original). The method of claim 26, wherein said antibody is a human antibody.

Claim 38 (Original). The method of claim 26, wherein said antibody is a humanized antibody.

Claim 39 (Original). The method of claim 26, wherein said antibody is a single-chain Fv antibody.

Claim 40 (Original). The method of claim 26, wherein said antibody is an Fab antibody fragment.

Claim 41 (Original). The method of claim 26, wherein said antibody is pegylated.

Claim 42 (Original). The method of claim 26, wherein said antibody is fused to a heterologous polypeptide.

Claim 43 (Original). The method of claim 26, wherein said first and second therapeutic agents are administered to the individual at the same time.

Claim 44 (Original). The method of claim 26, wherein said first and second therapeutic agents are administered to the individual at different times.

Claim 45 (Withdrawn). The method of claim 26, wherein said second therapeutic agent is TRAIL.

Claim 46 (Withdrawn). The method of claim 26, wherein said second therapeutic agent is a tumor necrosis factor blocking agent comprising an antibody that binds to a protein selected from the group consisting of:

- (a) TNF- α ;
- (b) TNF- β ;
- (c) TNF- γ ;
- (d) TNF- γ - α ; and
- (e) TNF- γ - β .

Claim 47 (Withdrawn). The method of claim 26, wherein said second therapeutic agent is an immunosuppressive agent selected from the group consisting of:

- (a) cyclosporine;
- (b) cyclophosphamide;
- (c) methylprednisone;
- (d) prednisone;
- (e) azathioprine;
- (f) FK-506; and
- (g) 15-deoxyspergualin.

Claim 48 (Withdrawn). The method of claim 26, wherein said second therapeutic agent is a cytokine selected from the group consisting of:

- (a) IL-2;
- (b) IL-3;
- (c) IL-4;
- (d) IL-5;
- (e) IL-6;
- (f) IL-7;
- (g) IL-10;
- (h) IL-12;
- (i) IL-13;
- (j) IL-15; and
- (k) IFN- γ .

Claim 49 (Original). The method of claim 26, wherein said second therapeutic agent is a chemotherapeutic agent selected from the group consisting of:

- (a) an alkylating agent;
- (b) an antimetabolite;
- (c) a farnesyl transferase inhibitor;
- (d) a mitotic spindle inhibitor;
- (e) a nucleotide analog;

- (f) a platinum analog; and
- (g) a topoisomerase inhibitor.

Claim 50 (Withdrawn). The method of claim 26, wherein said second therapeutic agent is a chemotherapeutic agent selected from the group consisting of:

- (a) ibritumomab tiuxetan (Zevalin™);
- (b) imatinib mesylate (Gleevec®);
- (c) bortezomib (Velcade™); and
- (d) a smac peptide or polypeptide.

Claim 51 (Original). A composition comprising:

(a) a first therapeutic agent comprising an antibody which binds to a polypeptide selected from the group consisting of:

- (i) amino acids 1 to 468 of SEQ ID NO:2, wherein said polypeptide is expressed on the surface of a cell;
- (ii) amino acids 24 to 468 of SEQ ID NO:2, wherein said polypeptide is expressed on the surface of a cell;
- (iii) amino acids 24 to 238 of SEQ ID NO:2, wherein said polypeptide is expressed on the surface of a cell;
- (iv) the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853, wherein said polypeptide is expressed on the surface of a cell;
- (v) the amino acid sequence of the mature polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853, wherein said polypeptide is expressed on the surface of a cell; and
- (vi) the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853, wherein said polypeptide is expressed on the surface of a cell;

and

- (b) a second therapeutic agent selected from the group consisting of:
 - (i) TRAIL;

- (ii) a tumor necrosis factor;
- (iii) a tumor necrosis factor blocking agent;
- (iv) an immunosuppressive agent;
- (v) an antibiotic;
- (vi) an anti-inflammatory agent;
- (vii) a chemotherapeutic agent; and
- (viii) a cytokine.

Claim 52 (Original). The composition of claim 51, which further comprises a pharmaceutically acceptable carrier.

Claim 53 (Original). The composition of claim 51, wherein said first therapeutic agent comprises an antibody which binds to a polypeptide consisting of amino acids 24 to 238 of SEQ ID NO:2.

Claim 54 (Original). The composition of claim 51, wherein said first therapeutic agent comprises an antibody which binds to a polypeptide consisting of the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853.

Claim 55 (Original). The composition of claim 51, wherein said antibody is an agonist of a polypeptide comprising amino acids 24 to 238 of SEQ ID NO:2.

Claim 56 (Original). The composition of claim 51, wherein said antibody is an agonist of a polypeptide comprising the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853.

Claim 57 (Original). The composition of claim 51, wherein said antibody is an antagonist of a polypeptide comprising amino acids 24 to 238 of SEQ ID NO:2.

Claim 58 (Original). The composition of claim 51, wherein said antibody is an antagonist of a polypeptide comprising the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853.

Claim 59 (Original). The composition of claim 51, wherein said antibody is an agonistic antibody.

Claim 60 (Original). The composition of claim 51, wherein said antibody is a monoclonal antibody.

Claim 61 (Original). The composition of claim 51, wherein said antibody is a polyclonal antibody.

Claim 62 (Original). The composition of claim 51, wherein said antibody is a chimeric antibody.

Claim 63 (Original). The composition of claim 51, wherein said antibody is a human antibody.

Claim 64 (Original). The composition of claim 51, wherein said antibody is a humanized antibody.

Claim 65 (Original). The composition of claim 51, wherein said antibody is a single-chain Fv antibody.

Claim 66 (Original). The composition of claim 51, wherein said antibody is an Fab antibody fragment.

Claim 67 (Original). The composition of claim 51, wherein said antibody is pegylated.

Claim 68 (Original). The composition of claim 51, wherein said antibody is fused to a heterologous polypeptide.

Claim 69 (Withdrawn). The composition of claim 51, wherein said second therapeutic agent is TRAIL.

Claim 70 (Withdrawn). The composition of claim 51, wherein said second therapeutic agent is a tumor necrosis factor blocking agent comprising an antibody that binds to a protein selected from the group consisting of:

- (a) TNF- α ;
- (b) TNF- β ;
- (c) TNF- γ ;
- (d) TNF- γ - α ; and
- (e) TNF- γ - β .

Claim 71 (Withdrawn). The composition of claim 51, wherein said second therapeutic agent is an immunosuppressive agent selected from the group consisting of:

- (a) cyclosporine;
- (b) cyclophosphamide;
- (c) methylprednisone;
- (d) prednisone;
- (e) azathioprine;
- (f) FK-506; and
- (g) 15-deoxyspergualin.

Claim 72 (Withdrawn). The composition of claim 51, wherein said second therapeutic agent is a cytokine selected from the group consisting of:

- (a) IL-2;
- (b) IL-3;
- (c) IL-4;
- (d) IL-5;

- (e) IL-6;
- (f) IL-7;
- (g) IL-10;
- (h) IL-12;
- (i) IL-13;
- (j) IL-15; and
- (k) IFN- γ .

Claim 73 (Original). The composition of claim 51, wherein said second therapeutic agent is a chemotherapeutic agent selected from the group consisting of:

- (a) an alkylating agent;
- (b) an antimetabolite;
- (c) a farnesyl transferase inhibitor;
- (d) a mitotic spindle inhibitor;
- (e) a nucleotide analog;
- (f) a platinum analog; and
- (g) a topoisomerase inhibitor.

Claim 74 (Withdrawn). The composition of claim 51, wherein said second therapeutic agent is a chemotherapeutic agent selected from the group consisting of:

- (a) ibritumomab tiuxetan (ZevalinTM);
- (b) imatinib mesylate (Gleevec[®]);
- (c) bortezomib (VelcadeTM); and
- (d) a smac peptide or polypeptide.

Claim 75 (Currently amended). A method for treating ~~a disease or condition~~
~~selected from the group consisting of:~~

- ~~(a) cancer;~~
- ~~(b) inflammation;~~
- ~~(c) an autoimmune disease; and~~
- ~~(d) graft v. host disease;~~

~~wherein said method comprises~~ comprising administering to an individual in need thereof, a therapeutically effective amount of the composition of claim 51.

Claim 76 (Original). A method for causing death of a cell, which expresses on its surface a polypeptide having an amino acid sequence selected from the group consisting of:

- (a) amino acids 24 to 468 of SEQ ID NO:2; and
- (b) amino acids 24 to 238 of SEQ ID NO:2;

wherein said method comprises contacting said cell with the composition of claim 51.

Claim 77 (Original). A method for causing death of a cell, which expresses on its surface a polypeptide having an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853;
- (b) the amino acid sequence of the mature polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853; and
- (c) the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853;

wherein said method comprises contacting said cell with the composition of claim 51.